SAVARA INC. (NASDAQ:SVRA) Files An 8-K Other Events
Item8.01.
| Other Events. |
As reported in its Current Report on Form 8-K filed on April28,
2017 Savara Inc. (f/k/a Mast Therapeutics, Inc.), a Delaware
corporation (the Company) entered into a Common Stock Sales
Agreement, dated April28, 2017 (the Sales Agreement), with H.C.
Wainwright Co., LLC, as sales agent (Wainwright), to which the
Company may offer and sell, from time to time, through
Wainwright, shares of the Companys common stock, par value $0.001
per share, having an aggregate offering price of not more than
$18.0 million. The material terms of the Sales Agreement are
described in the Companys Current Report on Form 8-K filed on the
April28, 2017. On May1, 2017, the Company filed a prospectus
supplement with the Securities and Exchange Commission in
connection with the Offering under its existing Registration
Statement on Form S-3 (File No 333-202960) .
Wilson Sonsini Goodrich Rosati P.C., counsel to the Company, has
issued a legal opinion relating to the Shares. A copy of such
legal opinion, including the consent included therein, is
attached as Exhibit 5.1 hereto.
This Current Report on Form 8-K shall not constitute an offer to
sell or the solicitation of an offer to buy the Shares, nor shall
there be any offer, solicitation or sale of the Shares in any
state or country in which such offer, solicitation or sale would
be unlawful prior to registration or qualification under the
securities laws of any such state or country.
| Item9.01. | Financial Statements and Exhibits. |
| (d) | Exhibits. |
|
Exhibit No. |
Description |
|
| 5.1 | Opinion of Wilson Sonsini Goodrich Rosati P.C. | |
| 23.1 |
Consent of Wilson Sonsini Goodrich Rosati P.C. (included in Exhibit 5.1) |
About SAVARA INC. (NASDAQ:SVRA)
Mast Therapeutics, Inc. is a biopharmaceutical company. The Company develops clinical-stage therapies for serious or life-threatening diseases with unmet needs. The Company focuses on developing new therapies for sickle cell disease, a chronic and genetic disorder classified as a rare, or orphan, disease in the United States of America and European Union, and for heart failure, a condition with an unmet need for treatment options. The Company’s segment is engaged in the business of developing therapies for serious or life-threatening diseases. The Company focuses on its Molecular Adhesion and Sealant Technology (MAST) platform, to develop MST-188 (vepoloxamer) Injection, its lead product candidate. The Company also develops AIR001, a sodium nitrite solution for intermittent inhalation through nebulizer. The Company’s AIR001 is in Phase II clinical development for the treatment of patients with HFpEF. SAVARA INC. (NASDAQ:SVRA) Recent Trading Information
SAVARA INC. (NASDAQ:SVRA) closed its last trading session 00.00 at 8.76 with 73,189 shares trading hands.